ProQR Therapeutics N.V. – NASDAQ:PRQR
Founder-led company
ProQR Therapeutics N.V. stock price today
$2.03
-0.76
-27.24%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 2 hours
ProQR Therapeutics N.V. stock price monthly change
+50.81%
month
ProQR Therapeutics N.V. stock price quarterly change
+50.81%
quarter
ProQR Therapeutics N.V. stock price yearly change
+38.81%
year
ProQR Therapeutics N.V. key metrics
Market Cap | 265.75M |
Enterprise value | 78.82M |
P/E | -2.24 |
EV/Sales | 22.82 |
EV/EBITDA | -1.10 |
Price/Sales | 38.64 |
Price/Book | 2.05 |
PEG ratio | 0.06 |
EPS | -0.33 |
Revenue | 10.25M |
EBITDA | -32.44M |
Income | -26.74M |
Revenue Q/Q | 583.38% |
Revenue Y/Y | 196.44% |
Profit margin | -2082.95% |
Oper. margin | -2017.54% |
Gross margin | 0% |
EBIT margin | -2017.54% |
EBITDA margin | -316.52% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProQR Therapeutics N.V. stock price history
ProQR Therapeutics N.V. stock forecast
ProQR Therapeutics N.V. financial statements
| Jun 2023 | 1.20M | -7.99M | -663.32% |
|---|---|---|---|
| Sep 2023 | 1.37M | -5.71M | -416.79% |
| Dec 2023 | 3.19M | -5.34M | -166.96% |
| Mar 2024 | 4.47M | -7.70M | -172.09% |
| Dec 2023 | 3.19M | -5.34M | -166.96% |
|---|---|---|---|
| Mar 2024 | 4.47M | -7.70M | -172.09% |
| Sep 2025 | 6.58M | -8.37M | -127.28% |
| Dec 2025 | 6.58M | -9.57M | -145.47% |
Analysts Price target
Financials & Ratios estimates
| 2023-05-03 | -0.12 | -0.22 |
|---|
| Jun 2023 | 147990000 | 96.49M | 65.2% |
|---|---|---|---|
| Sep 2023 | 142034000 | 95.69M | 67.37% |
| Dec 2023 | 137996680 | 96.57M | 69.98% |
| Mar 2024 | 123990806 | 89.13M | 71.89% |
| Jun 2023 | -10.34M | -294K | -643K |
|---|---|---|---|
| Sep 2023 | -7.50M | -339K | -281K |
| Dec 2023 | -5.48M | 4.87M | -1.05M |
| Mar 2024 | -15.22M | -17.83M | -421.46K |
ProQR Therapeutics N.V. alternative data
| Aug 2023 | 130 |
|---|---|
| Sep 2023 | 130 |
| Oct 2023 | 130 |
| Nov 2023 | 130 |
| Dec 2023 | 130 |
| Jan 2024 | 130 |
| Feb 2024 | 130 |
| Mar 2024 | 156 |
| Apr 2024 | 156 |
| May 2024 | 156 |
| Jun 2024 | 156 |
| Jul 2024 | 156 |
ProQR Therapeutics N.V. other data
44.59%
-28.97%
of PRQR is owned by hedge funds
58
-16
31.76M
-18.44M
shares is hold by hedge funds
| Insider | Compensation |
|---|---|
Mr. Daniel Anton de Boer (1983) Founder, Chief Executive Officer & Member of Management Board | $790,010 |
Ms. Theresa Marie Heggie (1960) Chief Commercial Officer | $40,690 |
-
What's the price of ProQR Therapeutics N.V. stock today?
One share of ProQR Therapeutics N.V. stock can currently be purchased for approximately $2.03.
-
When is ProQR Therapeutics N.V.'s next earnings date?
Unfortunately, ProQR Therapeutics N.V.'s (PRQR) next earnings date is currently unknown.
-
Does ProQR Therapeutics N.V. pay dividends?
No, ProQR Therapeutics N.V. does not pay dividends.
-
How much money does ProQR Therapeutics N.V. make?
ProQR Therapeutics N.V. has a market capitalization of 265.75M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 61.36% to 6.51M US dollars. ProQR Therapeutics N.V. made a loss 28.12M US dollars in net income (profit) last year or -$0.22 on an earnings per share basis.
-
What is ProQR Therapeutics N.V.'s stock symbol?
ProQR Therapeutics N.V. is traded on the NASDAQ under the ticker symbol "PRQR".
-
What is ProQR Therapeutics N.V.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ProQR Therapeutics N.V.?
Shares of ProQR Therapeutics N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ProQR Therapeutics N.V.'s key executives?
ProQR Therapeutics N.V.'s management team includes the following people:
- Mr. Daniel Anton de Boer Founder, Chief Executive Officer & Member of Management Board(age: 42, pay: $790,010)
- Ms. Theresa Marie Heggie Chief Commercial Officer(age: 65, pay: $40,690)
-
Is ProQR Therapeutics N.V. founder-led company?
Yes, ProQR Therapeutics N.V. is a company led by its founder Mr. Daniel Anton de Boer.
-
How many employees does ProQR Therapeutics N.V. have?
As Jul 2024, ProQR Therapeutics N.V. employs 156 workers.
-
When ProQR Therapeutics N.V. went public?
ProQR Therapeutics N.V. is publicly traded company for more then 11 years since IPO on 18 Sep 2014.
-
What is ProQR Therapeutics N.V.'s official website?
The official website for ProQR Therapeutics N.V. is proqr.com.
-
How can i contact ProQR Therapeutics N.V.?
ProQR Therapeutics N.V. can be reached via phone at +31 88 166 7000.
ProQR Therapeutics N.V. company profile:
ProQR Therapeutics N.V.
proqr.comExchange:
NASDAQ
Full time employees:
156
Industry:
Biotechnology
Sector:
Healthcare
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Zernikedreef 9
Leiden, 2333 Ck
Leiden, 2333 Ck
CIK: 0001612940
ISIN: NL0010872495
CUSIP: N71542109
